This Third World Network article examines the parallels between the production, marketing and distribution strategies of (1) antiviral medicine oseltamivir (Tamiflu) by Roche for H1N1 in the years 2005 and 2009 and (2) remdesivir by Gilead Sciences for Covid-19 during this pandemic.
Read here (Third World Network, July 10, 2020)
